Sensitivity and Proportionality Assessment of Metabolites from Microdose to High Dose in Rats Using LC–MS/MS

• Sudo K . Microdosing for reduction of the time and resources for drug development. Drug Metab. Pharmacokinet. 22(5), 327 (2007).
   PubMed Web of Science ®Google Scholar
• Poggesi I . Predicting human pharmacokinetics from preclinical data. Curr. Opin. Drug Discov. Devel. 7(1), 100–111 (2004).
   PubMed Web of Science ®Google Scholar
• Obach RS , BaxterJG, ListonTEet al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. 283(1), 46–58 (1997).
   PubMed Web of Science ®Google Scholar
• Kola I , LandisJ. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711–716 (2004).
   PubMed Web of Science ®Google Scholar
• Mahmood I . Allometric issues in drug development. J. Pharm. Sci. 88(11), 1101–1106 (1999).
   PubMed Web of Science ®Google Scholar
• Grass GM , SinkoPJ. Physiologically-based pharmacokinetic simulation modeling. Adv. Drug Deliv. Rev. 54(3), 433–451 (2002).
   PubMed Web of Science ®Google Scholar
• Lappin G , GarnerRC. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat. Rev. Drug Discov. 2(3), 233–240 (2003).
   PubMed Web of Science ®Google Scholar
• Balani SK , NagarajaNV, QianMGet al. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography–tandem mass spectrometry. Drug Metab. Dispos. 34(3), 384–388 (2006).
   PubMed Web of Science ®Google Scholar
• Lappin G , KuhnzW, JochemsenRet al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with five drugs. Clin. Pharmacol. Ther. 80(3), 203–215 (2006).
   PubMed Web of Science ®Google Scholar
• Ni J , OuyangH, AielloMet al. Microdosing assessment to evaluate pharmacokinetics and drug metabolism in rats using liquid chromatography-tandem mass spectrometry. Pharm. Res. 25(7), 1572–1582 (2008).
   PubMed Web of Science ®Google Scholar
• Sandhu P , VogelJS, RoseMJet al. Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. Drug Metab. Dispos. 32(11), 1254–1259 (2004).
   PubMed Web of Science ®Google Scholar
• Vuong LT , RuckleJL, BloodABet al. Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine. J. Pharm. Sci. 97(7), 2833–2843 (2008).
   PubMed Web of Science ®Google Scholar
• Yamane N , TozukaZ, SugiyamaY, TanimotoT, YamazakiA, KumagaiY. Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 858(1–2), 118–128 (2007).
   PubMed Web of Science ®Google Scholar
• Madan A , O’BrienZ, WenJet al. A pharmacokinetic evaluation on five H1 antagonists after an oral and intravenous microdose to human subjects. Br. J. Clin. Pharmacol. 67(3), 288–298 (2009).
   PubMed Web of Science ®Google Scholar
• Miyaji Y , IshizukaT, KawaiKet al. Use of an intravenous microdose of 14C-labeled drug and accelerator mass spectrometry to measure absolute oral bioavailability in dogs; cross-comparison of assay methods by accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry. Drug Metab. Pharmacokinet. 24(2), 130–138 (2009).
   PubMed Web of Science ®Google Scholar
• Minamimoto R , HamabeY, MiyaokaTet al. Accelerator mass spectrometry analysis of background 14C-concentrations in human blood: aiming at reference data for further microdosing studies. Ann. Nucl. Med. 22, 883–889 (2008).
   PubMed Web of Science ®Google Scholar
• Lappin G , GarnerRG. The utility of microdosing over the past 5 years. Expert Opin. Drug Metab. Toxicol. 4(12), 1499–1506 (2008).
   PubMed Web of Science ®Google Scholar
• Garner RC . Less is more: the human microdosing concept. Drug Discov. Today10(7), 449–451 (2005).
   PubMed Web of Science ®Google Scholar
• Lappin G , GarnerRC. The use of accelerator mass spectrometry to obtain early human ADME/PK data. Expert Opin. Drug Metab. Toxicol. 1(1), 23–31 (2005).
   PubMedGoogle Scholar
• Sudo K , OkazakiO, TsumuraM, TachizawaH. Isolation and identification of metabolites of ofloxacin in rats, dogs and monkeys. Xenobiotica16(8), 725–732 (1986).
   PubMed Web of Science ®Google Scholar
• Wong FA , FlorSC. The metabolism of ofloxacin in humans. Drug Metab. Dispos. 18(6), 1103–1104 (1990).
   PubMed Web of Science ®Google Scholar
• Hoffmann K . Identification of the main urinary metabolites of omeprazole after an oral dose to rats and dogs. Drug Metab. Dispos. 14(3), 341–348 (1986).
   PubMed Web of Science ®Google Scholar
• Renberg L , SimonssonR, HoffmannK. Identification of two main urinary metabolites of [14C]-omeprazole in humans. Drug Metab. Dispos. 17(1), 69–76 (1989).
   PubMed Web of Science ®Google Scholar
• Poon G , ChuiY, McCagueRet al. Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. Drug Metab. Dispos. 21(6), 1119–1124 (1993).
   PubMed Web of Science ®Google Scholar
• Fromson JM , PearsonS, BramahS. The metabolism of tamoxifen (ICI 46474). Part I: in laboratory animals. Xenobiotica3, 693–709 (1973).
   PubMed Web of Science ®Google Scholar
• Black A , HayesR, RothB, WooP, WoolfT. Metabolism and excretion of atorvastatin in rats and dogs. Drug Metab. Dispos. 27(8), 916–923 (1999).
   PubMed Web of Science ®Google Scholar
• Fromson JM , PearsonS, BramahS. The metabolism of tamoxifen (ICI 46474). Part II: in female patients. Xenobiotica3, 711–714 (1973)
   PubMed Web of Science ®Google Scholar
• Shin SC , ChoiJS, LiX. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int. J. Pharm. 313(1–2), 144–149 (2006).
   PubMedGoogle Scholar
• Lee DY , ShinHS, LeeI, LeeMG. Pharmacokinetics of omeprazole in rats with water deprivation for 72 hours. Biopharm. Drug Dispos. 27(8), 361–370 (2006).
   PubMed Web of Science ®Google Scholar
• Lennernas H . Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet. 42(13), 1141–1160 (2003).
   PubMed Web of Science ®Google Scholar
• Kocarek TA , DahnMS, CaiH, StromSC, Mercer-HainesNA. Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes. Drug Metab. Dispos. 30(12), 1400–1405 (2002).
   PubMed Web of Science ®Google Scholar
• Hoffmann M , NowosielskiM. DFT study on hydroxy acid-lactone interconversion of statins: the case of atorvastatin. Org. Biomol. Chem. 6(19), 3527–3531 (2008).
   PubMed Web of Science ®Google Scholar
• Michniewicz BM , BlackAE, SinzMW, WoolfTF. in vitro and in vivo metabolism of atorvastatin (CI-981). ISSX Proc. 6, 93 (1994).
   Google Scholar
• Halpin RA , UlmEH, TillAEet al. Biotransformation of lovastatin V: species differences in vivo metabolite profiles of mouse, rat, dog, and human. Drug Metab. Dispos. 21, 1003–1011 (1993).
   PubMed Web of Science ®Google Scholar
• Boberg M , AngerbauerR, FeyPet al. Biotransformation of cervastatin in mice, rats, and dogs in vivo. Drug Metab. Dispos. 26, 640–652 (1998).
   PubMed Web of Science ®Google Scholar
• Kantola T , KivistoKT, NeuvonenPJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin. Pharmacokinet. Ther. 64, 58–65 (1998).
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T , MaB, FangX, SubramanianR, YuJ, LinJH. b-oxidation of simvastatin in mouse liver preparations. Drug Metab. Dispos. 29(10), 1251–1255 (2001).
   PubMed Web of Science ®Google Scholar
• Li C , SubramanianR, YuS, PrueksaritanontT. Acyl-coenzyme A formation of simvastatin in mouse liver preparations. Drug Metab. Dispos. 34(1), 102–110 (2006).
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T , SubramanianR, FangXet al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab. Dispos. 30(5), 505–512 (2002).
   PubMed Web of Science ®Google Scholar

Websites

• US FDA. Guidance for industry, investigators, and reviewers – exploratory IND studies. January (2006) www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078933.pdf
   Google Scholar
• European Medicines Agency (EMEA), Committee for Medicinal Products for Human Use (CHMP). Position paper on non-clinical safety studies to support clinical trials with a single microdose. CPMP, SWP, 2599, 02, Rev 1, London, 23 June (2004) www.ema.europa.eu/pdfs/human/swp/259902en.pdf
   Google Scholar
• Food and Drug Administration. Safety testing of drug metabolites. February (2008) www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf
   Google Scholar